AMR BIO: CONSTRUCTIVE TYPE B FDA MEETING FOR XF-73

Summary by AI BETAClose X

EMV Capital's portfolio company AMR Bio, in which EMV holds a direct 29.7% interest, received constructive FDA Type B (EOP2) meeting minutes for XF-73 Nasal after a Phase 2b result showing a 99.5% reduction in Staphylococcus aureus nasal carriage; the FDA was supportive of AMR Bio's proposed Phase 3 design, provided recommendations to be incorporated, and AMR Bio expects to submit full Phase 3 protocols in the coming months. The regulatory milestone was achieved within c.14 months of company formation and XF-73 holds QIDP and Fast Track designations that confer an additional five years of US market exclusivity, enhancing commercial and valuation prospects.

Disclaimer*

Companies

Emv Capital (EMVC)
UK 100

Latest directors dealings